Back to top
more

Spero Therapeutics (SPRO)

(Delayed Data from NSDQ)

$2.28 USD

2.28
7,179,830

+0.17 (8.06%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $2.26 -0.02 (-0.88%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

by Zacks Equity Research

Per GRFS, Brookfield's offer to buy its entire outstanding share capital for 6.45 billion euros significantly undervalues GRFS' prospects and long-term potential.

Zacks Equity Research

FATE Presents Encourgaing Data From Lupus Study, Stock Gains

by Zacks Equity Research

Fate Therapeutics presents promising data on FT819 showing the first patient treated experienced a favorable clinical experience, achieved drug-free clinical remission, and continues on-study.

Zacks Equity Research

CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC

by Zacks Equity Research

The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free survival by more than three years in certain NSCLC patients.

Zacks Equity Research

CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC

by Zacks Equity Research

The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of disease progression or death by 30% in certain NSCLC patients.

Zacks Equity Research

New Strong Buy Stocks for November 15th

by Zacks Equity Research

FHI, RJF, ASTS, APLD and SPRO have been added to the Zacks Rank #1 (Strong Buy) List on November 15, 2024.

Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Spero Therapeutics (SPRO) delivered earnings and revenue surprises of -18.52% and 41.44%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of -17.81% and 18.15%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Repligen (RGEN) delivered earnings and revenue surprises of 26.47% and 1.19%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

ADC Therapeutics (ADCT) delivered earnings and revenue surprises of -16.67% and 1.56%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Equillium, Inc. (EQ) to Report Q3 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Equillium (EQ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.